VEGF Trap-Eye (BAY86-5321)
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Myopia, Pathological
Conditions
Myopia, Pathological
Trial Timeline
Dec 1, 2010 → Aug 1, 2013
NCT ID
NCT01249664About VEGF Trap-Eye (BAY86-5321)
VEGF Trap-Eye (BAY86-5321) is a phase 3 stage product being developed by Regeneron Pharmaceuticals for Myopia, Pathological. The current trial status is completed. This product is registered under clinical trial identifier NCT01249664. Target conditions include Myopia, Pathological.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01512966 | Phase 3 | Completed |
| NCT01249664 | Phase 3 | Completed |
Competing Products
5 competing products in Myopia, Pathological
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| DE-127 Ophthalmic Solution low dose + DE-127 Ophthalmic Solution medium dose + DE-127 Ophthalmic Solution high dose + Placebo Ophthalmic Solution | Santen Pharmaceutical | Phase 2 | 52 |
| Ranibizumab 0.5mg + Ranibizumab 0.5 mg + Verteporfin PDT | Novartis | Phase 3 | 77 |
| Ranibizumab + Verteporfin PDT + Sham Ranibizumab + Sham verteporfin PDT | Novartis | Phase 3 | 77 |
| Ranibizumab | Novartis | Phase 3 | 77 |
| Faricimab + Ranibizumab | Roche | Phase 3 | 77 |